血清EBV-miR-BART13-3P在青海地区慢性乙型肝炎肝纤维化患者中的表达及诊断价值

李萍英; 杨永耿; 李娟; 沈有秀; 马颖才; 陆伦根

doi:10.3969/j.issn.1001-5256.2019.04.014

血清EBV-miR-BART13-3P在青海地区慢性乙型肝炎肝纤维化患者中的表达及诊断价值

DOI: 10.3969/j.issn.1001-5256.2019.04.014

1. 青海省人民医院消化科
2. 上海市交通大学附属第一人民医院消化科

基金项目:

中国肝炎防治基金会天晴肝病基金项目(TQGB20140260)；

详细信息

中图分类号: R512.62;R575.2
计量
- 文章访问数: 1451
- HTML全文浏览量: 54
- PDF下载量: 289
- 被引次数: 0
出版历程
- 出版日期: 2019-04-20

Expression of serum EBV-miR-BART13-3p and its diagnostic value in patients with chronic hepatitis B liver fibrosis in Qinghai, China

Department of Gastroenterology, Qinghai Provincial People′s Hospital

Research funding:

摘要

摘要: 目的通过比较青海地区不同肝纤维化进程的慢性乙型肝炎（CHB）患者血清EBV-miR-BART13-3P表达差异,探讨血清EBV-miR-BART13-3P在青海地区CHB肝纤维化中的诊断价值。方法选取2015年7月-2017年3月期间青海省人民医院消化科收治的100例CHB肝纤维化患者及20例门诊体检正常人群,通过肝脏瞬时弹性成像检测系统（FibroTouch）进行纤维化分期（F0～4）。分为对照组（n=20）、F0～2组（n=36）、F2～4组（n=44）和肝硬化组（n=20）共4组。采用real-time PCR法检测血清EBV-miR-BART13-3P,比较各组间血清EBV-miR-BART13-3P的表达差异。计量资料多组间比较采用单因素方差分析,组间进一步比较采用LSD-t检验;计数资料组间比较采用χ2检验。采用Pearson相关分析比较血清EBV-miR-BART13-3P与肝脏硬度测定值（LSM值）的相关性,并采用受试者工作特征曲线评价血清EBV-miR-BART13-3P与肝纤维化指标[Ⅲ型前胶原（PCⅢ）、透明质酸（HA）]在CHB肝纤维化中的...
- 肝炎,乙型,慢性 /
- 肝硬化 /
- 微RNAs /
- 诊断 /
- 青海
Abstract: Objective To investigate the difference in the expression of serum EBV-miR-BART13-3 p between chronic hepatitis B ( CHB) patients with different liver fibrosis stages in Qinghai, China and the value of serum EBV-miR-BART13-3 p in the diagnosis of CHB liver fibrosis. Methods A total of 100 patients with CHB liver fibrosis who were admitted to Department of Gastroenterology, Qinghai Provincial People's Hospital, from July 2015 to March 2017 were enrolled, and according to fibrosis stage ( F0-F4) determined by liver transient elastography ( FibroTouch) , they were divided into F0-F2 group with 36 patients, F2-F4 group with 44 patients, and liver cirrhosis group with 20 patients. A total of 20 normal individuals who underwent physical examination were enrolled as control group. Real-time PCR was used to measure serum EBV-miR-BART13-3 p, and the expression of serum EBV-miR-BART13-3 p was compared between groups. A one-way ANOVA was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups; the chi-square test was used for comparison of categorical data between groups. A bivariate correlation analysis was used to investigate the correlation between serum EBV-miR-BART13-3 p and liver stiffness measurement ( LSM) , and the receiver operating characteristic ( ROC) curve was used to investigate the value of serum EBV-miR-BART13-3 p and liver fibrosis indices [procollagen type Ⅲ ( PCⅢ) and hyaluronic acid ( HA) ] in the diagnosis of CHB liver fibrosis.Results The F0-F2 group, the F2-F4 group, and the liver cirrhosis group had significantly higher expression of serum EBV-miR-BART13-3 p than the control group ( 8. 91 ± 2. 33/14. 89 ± 4. 24/36. 56 ± 4. 24 vs 1. 01 ± 0. 57, F = 219. 42, P < 0. 001) . Serum EBV-miR-BART13-3 p had an area under the ROC curve ( AUC) of 0. 970, a sensitivity of 96. 9%, and a specificity of 88. 9% at the cut-off value of 10. 10; PⅢ had an AUC of 0. 632, a sensitivity of 31. 3%, and a specificity of 100% at the cut-off value of 47. 58 ng/ml; HA had an AUC of 0. 670, a sensitivity of 81. 3%, and a specificity of 55. 6% at the cut-off value of 85. 52 ng/ml. Serum EBV-miR-BART13-3 p was positively correlated with LSM ( r = 0. 797, P < 0. 001) . For the patients with the same stage of CHB liver fibrosis, there was no significant difference in the expression of serum EBV-miR-BART13-3 p between the patients in different ethnic groups or living at different altitudes in Qinghai ( all P > 0. 05) . Conclusion The expression of serum EBV-miR-BART13-3 p is gradually increasing with the progression of CHB liver fibrosis in Qinghai. Serum EBV-miR-BART13-3 p has a high value in the diagnosis of CHB liver fibrosis.Ethnic background and altitude have no marked influence on the expression of serum EBV-miR-BART13-3 p.
- hepatitis B, chronic /
- liver cirrhosis /
- micrornas /
- diagnosis /
- QINGHAI

HTML全文

参考文献(19)

[1]JIANG HF, CHEN Z, FANG RH, et al. Epidemic analysis of hepatitis B in China during 2004-2012[J]. Chin J Health Lab Tec, 2015, 25 (3) :408-411. (in Chinese) 姜慧芬, 陈卓, 方任华, 等.我国2004年-2012年乙型病毒性肝炎疫情分析[J].中国卫生检验杂志, 2015, 25 (3) :408-411.

[2]MANNING DS, AFDHAL NH. Diagnosis and quantitation of fibrosis[J]. Gastroenterology, 2008, 134 (6) :1670-1681.

[3]ZHANG Q, XU M, QU Y, et al. Analysis of the differential expression of circulating microRNAs during the progression of hepatic fibrosis in patients with chronic hepatitis B virus infection[J]. Mol Med Rep, 2015, 12 (4) :5647-5654.

[4]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[5]SONG Y, WANG F, HUANG Q, et al. MicroRNAs contribute to hepatocellular carcinoma[J]. Mini Rev Med Chem, 2015, 15 (6) :459-466.

[6]LUO Y, HAN ZW, TIAN N, et al. Research progress on the relationship between miRNAs and common liver disease[J]. J Zhejiang Chin Med Univ, 2014, 38 (1) :110-114. (in Chinese) 罗阳, 韩子午, 田男, 等. miRNA与常见肝病发生发展关系的研究进展[J].浙江中医药大学学报, 2014, 38 (1) :110-114.

[7]LIU SJ, HAO YQ, CHEN J, et al. Expression of miR-122 in serum of patients with HBV-related acute-on-chronic liver failure and theclinical significance[J/CD]. Chin J Exp Clin Infect Dis:Electronic Edition, 2017, 11 (6) :539-544. (in Chinese) 刘士军, 郝彦琴, 陈杰, 等.乙型肝炎相关慢加急性肝功能衰竭患者血清中miR-122的表达及其临床意义[J/CD].中华实验和临床感染病杂志:电子版, 2017, 11 (6) :539-544.

[8]ZHANG LD, LIU J, REN XJ, et al. Differences of miRNA expression profiling in normal liver, liver cirrhosis, HBV-related liver cancer tissues[J]. Chin J Nosocomiol, 2016, 26 (4) :749-751. (in Chinese) 张良东, 刘杰, 任晓娟, 等.正常肝脏与乙型肝炎肝硬化及乙型肝炎病毒相关性肝癌组织中miRNA表达谱差异[J].中华医院感染学杂志, 2016, 26 (4) :749-751.

[9] XU MD, LI WQ, YU HY. Research on microRNA in liver disease and hepatic fibrosis[J]. Chin J Pathology, 2011, 40 (1) :65-67. (in Chinese) 许蜜蝶, 李维卿, 余宏宇. Micro RNA与肝病及肝纤维化相关研究[J].中华病理学杂志, 2011, 40 (1) :65-67.

[10]ZHENG J, ZHOU Z, XU Z, et al. Serum microRNA-125a-5p, a useful biomarker in liver diseases, correlates with disease progression[J]. Mol Med Rep, 2015, 12 (1) :1584-1590.

[11]HUANG CF, SUN CC, ZHAO F, et al. miR-33a levels in hepatic and serum after chronic HBV-induced fibrosis[J]. J Gastroenterol, 2015, 50 (4) :480-490.

[12]LI PY, YANG YG, LU LG, et al. Value of microRNAs in diagnosis of chronic hepatitis B-related liver fibrosis[J]. J Clin Hepatol, 2017, 33 (12) :2412-2415. (in Chinese) 李萍英, 杨永耿, 陆伦根, 等. microRNA在慢性乙型肝炎肝纤维化中的诊断价值[J].临床肝胆病杂志, 2017, 33 (12) :2412-2415.

[13]APPOURCHAUX K, DOKMAK S, RESCHE-RIGON M, et al.MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C[J]. Sci Rep, 2016, 6:34935.

[14]CHEN R, WU JC, LIU T, et al. MicroRNA profile analysis in the liver fibrotic tissues of chronic hepatitis B patients[J]. J Dig Dis, 2017, 18 (2) :115-124.

[15]YANG YQ, ZHANG H, LI X, et al. A cross-sectional survey of relationship between hepatitis B virus and hepatitis C virus co-infected with Epstein-barr virus infection and liver cirrhosis[J/CD]. Chin J Liver Dis:Electronic Version, 2015, 7 (4) :90-93. (in Chinese) 杨玉奇, 张慧, 李昕, 等.乙型肝炎、丙型肝炎合并EB病毒感染与肝硬化发生的横断面研究[J/CD].中国肝脏病杂志:电子版, 2015, 7 (4) :90-93.

[16]LI JF, CAI MD, ZHONG L, et al. Expression and significance of EB virus micro RNA in nasopharyngeal cancer[J]. Practical J Cancer, 2018, 33 (2) :175-176. (in Chinese) 李剑飞, 蔡茂德, 钟亮, 等. EB病毒微小RNA在鼻咽癌患者中表达的意义[J].实用癌症杂志, 2018, 32 (2) :175-176.

[17]GALLO A, JANG SI, ONG HL, et al. Targeting the Ca (2+) Sensor STIM1 by exosomal transfer of EBV-miR-BART13-3P is associated with Sjogren's Syndrome[J]. EBio Medicine, 2016, 10:216-226.

[18]KOMABAYASHI Y, KISHIBE K, NAGATO T, et al. Circulating Epstein-Barr virus-encoded micro-RNAs as potential biomarkers for nasal natural killer/T-cell lymphoma[J]. Hematol Oncol, 2017, 35 (4) :655-663.

[19]SHIHA G, IBRAHIM A, HELMY A, et al. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis:A 2016 update[J]. Hepatol Int, 2017, 11 (1) :1-30

施引文献

资源附件(0)

访问统计